| 1654 |
National Cancer Institute |
Html |
en |
Gerson Therapy (PDQ®)–Health Professional Version |
Expert-reviewed information summary about Gerson therapy as a treatment for people with cancer. Note: The information in this summary is no longer being updated and is provided for reference purposes only. |
| complex regimen | 0.484073 |
| prescribed conventional regimen | 0.48627 |
| body | 0.480118 |
| treatment regimen | 0.476762 |
| New York City | 0.503592 |
| American Cancer Society | 0.4659 |
| normal metabolic state | 0.454242 |
| Gerson’s data | 0.572285 |
| coffee enemas | 0.55048 |
| Gerson Research Organization | 0.580725 |
| cancer information summary | 0.482421 |
| cancer therapies | 0.454018 |
| colorectal cancer | 0.455812 |
| diet regimen | 0.532413 |
| Gerson therapy | 0.918805 |
| patients | 0.555703 |
| cancer patients | 0.512802 |
| Gerson’s life | 0.570445 |
| Gerson regimen | 0.719238 |
| flaxseed oil | 0.455436 |
| diet group | 0.469079 |
| Charlotte Gerson Straus | 0.587654 |
| injectable crude liver | 0.462964 |
| gonzalez regimen | 0.487953 |
| potassium | 0.46778 |
|
| United States | 0.4578 |
| Gerson approach | 0.560315 |
| cancer cells | 0.467412 |
| 5-year survival rate | 0.480223 |
| cancer cell biology | 0.469353 |
| Gerson regimen. | 0.568736 |
| A. Pancreatic enzymes | 0.456434 |
| potassium solution | 0.46218 |
| excess sodium | 0.454821 |
| Gerson Hospital | 0.567697 |
| Gerson approach. | 0.560098 |
| National Cancer Institute | 0.466567 |
| Desiccated liver capsules | 0.461935 |
| stage I–II patients | 0.465698 |
| New York | 0.508367 |
| Gerson segment | 0.563678 |
| pancreatic enzymes | 0.529579 |
| Gerson Institute | 0.579619 |
| healthy liver function. | 0.462886 |
| Gerson diet | 0.622931 |
| crude liver extract | 0.544679 |
| melanoma patients | 0.45525 |
| cancer | 0.570183 |
| Max Gerson | 0.650691 |
|
CLICK HERE |
| 1697 |
National Cancer Institute |
Html |
en |
High-Dose Vitamin C (PDQ®)–Patient Version |
Expert-reviewed information summary about the use of high-dose vitamin C as a treatment for people with cancer. |
| cancer treatment | 0.409014 |
| Vitamin C levels | 0.46062 |
| chemotherapy | 0.385658 |
| PDQ cancer information | 0.495143 |
| Cancer Complementary | 0.400016 |
| vitamin C therapy | 0.473688 |
| vitamin C. Patients | 0.500759 |
| vitamin C. Studies | 0.500091 |
| clinical trials | 0.625144 |
| cancer information summary | 0.452988 |
| laboratory studies | 0.446817 |
| alternative cancer therapies | 0.39781 |
| clinical trial | 0.386901 |
| high doses | 0.433559 |
| prostate cancer cells | 0.388026 |
| CAM cancer research | 0.38618 |
| ovarian cancer | 0.395778 |
| malignant mesothelioma | 0.387621 |
| High-Dose Vitamin C. | 0.544572 |
| patients | 0.543391 |
| cancer patients | 0.435773 |
| NCI PDQ cancer | 0.414799 |
| cancer information database | 0.396035 |
| effects | 0.387385 |
|
| Therapies Editorial Board | 0.399092 |
| cancer information | 0.505736 |
| treatment | 0.52957 |
| breast cancer cells | 0.389833 |
| intravenous high-dose vitamin | 0.577226 |
| Complementary Therapies Editorial | 0.414088 |
| Drug Administration | 0.422556 |
| Cancer Information Specialist | 0.391085 |
| dehydroascorbic acid | 0.390795 |
| cancer cells | 0.552348 |
| Cancer Information Service | 0.451182 |
| anticancer drugs | 0.396426 |
| high-dose ascorbic acid | 0.545315 |
| National Cancer Institute | 0.563244 |
| alternative medicine | 0.442263 |
| health care | 0.392613 |
| advanced pancreatic cancer | 0.416341 |
| high-dose IV vitamin | 0.624976 |
| vitamin C treatment | 0.515175 |
| breast cancer | 0.420605 |
| animal studies | 0.461706 |
| alternative therapies | 0.414436 |
| high-dose vitamin | 0.916436 |
| cancer information summaries | 0.396462 |
|
CLICK HERE |
| 1786 |
National Cancer Institute |
Html |
es |
Linfedema (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca del tratamiento del linfedema. |
| siguientes áreas | 0.436931 |
| causa hinchazón | 0.778344 |
| pequeña cantidad | 0.464081 |
| pequeños cortes | 0.452311 |
| siguientes abordajes | 0.459419 |
| PDQ Linfedema | 0.618416 |
| sección información | 0.436578 |
| largo plazo | 0.580542 |
| protector solar | 0.453778 |
| sección manejo | 0.432902 |
| National Cancer Institute | 0.432858 |
| ropa flojos | 0.450402 |
| siguientes riesgos | 0.424859 |
|
| Instituto Nacional | 0.463187 |
| siguientes problemas | 0.490486 |
| linfedema atrapa | 0.967072 |
| Physician Data Query | 0.535003 |
| Estados Unidos | 0.442188 |
| estadio iii | 0.728645 |
| siguientes medidas | 0.469803 |
| linfa circula | 0.531655 |
| linfedema.ampliar anatomÃa | 0.480452 |
| siguientes pruebas | 0.475048 |
| uñas ayuda | 0.454713 |
| baja potencia | 0.433231 |
|
CLICK HERE |
| 1873 |
National Cancer Institute |
Html |
es |
Tratamiento del sarcoma uterino (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca del tratamiento del sarcoma uterino. |
| Obstet Gynecol | 0.426292 |
| Major FJ | 0.422403 |
| sarcomas uterinos | 0.471793 |
| cisplatin as | 0.411109 |
| Markman M | 0.40448 |
| gynecologic cancer | 0.405911 |
| prognostic factors | 0.405684 |
| Brunetto VL | 0.40512 |
| Sin embargo | 0.405423 |
| or without paclitaxel | 0.411277 |
| fase ii | 0.413551 |
| Ifosfamide treatment | 0.404047 |
| endometrial stromal sarcoma | 0.415162 |
| Radiat Oncol Biol | 0.40725 |
| siguientes puntos | 0.405418 |
| oncology group study | 0.684258 |
| stromal sarcomas previously | 0.409618 |
| patologÃa equivocada | 0.404764 |
| Barrett RJ | 0.404588 |
| Kilgore L | 0.404374 |
| recurrent or metastatic | 0.405758 |
| mixed mesodermal tumors | 0.448955 |
| Gynecologic Oncology Group | 0.969258 |
| Gynecol Oncol | 0.445429 |
| Filiaci V | 0.404525 |
|
| Beecham J | 0.404572 |
| or recurrent leiomyosarcoma | 0.405872 |
| Blessing JA | 0.5678 |
| meses vs | 0.434084 |
| Organización Mundial | 0.408363 |
| pilot study | 0.40409 |
| sarcomas mesodérmicos mixtos | 0.406902 |
| Smith MR | 0.405644 |
| as second-line chemotherapy | 0.406079 |
| or recurrent | 0.412147 |
| New York | 0.404218 |
| Peters WA | 0.405698 |
| Clin Oncol | 0.49692 |
| combination chemotherapy | 0.409211 |
| verdaderos sarcomas | 0.414072 |
| Oncol Biol Phys | 0.407314 |
| cuerpo uterino | 0.408492 |
| elementos homólogos | 0.406306 |
| estadio iii | 0.405213 |
| Rosenshein N | 0.4046 |
| stromal sarcoma | 0.431127 |
| Homesley HD | 0.404643 |
| dimethyl triazenoimidazole carboxamide | 0.404595 |
| with or without | 0.432244 |
|
CLICK HERE |
| 2001 |
National Cancer Institute |
Html |
es |
Familiares a cargo de pacientes de cáncer: funciones y desafíos (PDQ®)–Versión para profesionales de salud |
Sumario informativo revisado por expertos acerca de los desafíos que enfrentan los familiares a cargo de los pacientes con cáncer. Este resumen se centra en las funciones típicas y las inquietudes de las personas a cargo del paciente y en las intervenciones útiles para esas personas. |
| etapa final | 0.435131 |
| Cancer Communication Assessment | 0.482566 |
| giving bad news | 0.42261 |
| to breast | 0.424042 |
| Sin embargo | 0.471583 |
| receiving palliative care | 0.419812 |
| American Cancer Society | 0.47018 |
| Family support | 0.41866 |
| family to breast | 0.421621 |
| CA Cancer | 0.459636 |
| Given BA | 0.442227 |
| Communication Assessment Tool | 0.434693 |
| Rose JH | 0.438883 |
| family meetings | 0.426208 |
| Estados Unidos | 0.421866 |
| Support Care | 0.447919 |
| Caregivers Based | 0.422755 |
| Palliat Care | 0.44789 |
| patients with | 0.44256 |
| Pain Symptom Manage | 0.455568 |
| Support Oncol | 0.41857 |
| Baile WF | 0.422726 |
| Family Caregiver Support | 0.426151 |
| family caregivers | 0.94013 |
| Crit Care Nurs | 0.421936 |
|
| Oncol Nurs Forum | 0.49008 |
| with family caregivers | 0.435774 |
| Care Cancer | 0.474055 |
| Cancer Facts | 0.43863 |
| Arnold RM | 0.422137 |
| palliative care | 0.565514 |
| Hosp Palliat Care | 0.420581 |
| paciente cumpla | 0.459325 |
| terminally ill patients | 0.428058 |
| Family caregiver quality | 0.42241 |
| communication skills | 0.434733 |
| cancer pain | 0.552042 |
| Crit Care | 0.427432 |
| Palliat Med | 0.438559 |
| Given CW | 0.427811 |
| breast cancer | 0.524972 |
| Arch Intern Med | 0.454734 |
| Conducting family meetings | 0.417671 |
| Baider L | 0.421555 |
| caregivers with | 0.421979 |
| placing family meetings | 0.417694 |
| Crit Care Med | 0.422158 |
| symptoms among caregivers | 0.425057 |
| cancer communication | 0.540368 |
|
CLICK HERE |
| 2023 |
National Cancer Institute |
Html |
es |
Prevención del cáncer de seno (mama) (PDQ®)–Versión para pacientes |
Sumario de información revisada por expertos sobre factores que influyen en el riesgo de presentar cáncer de mama y sobre las investigaciones dirigidas a la prevención de esta enfermedad. |
| Risk Assessment Tool | 0.639814 |
| enfermedad benigna | 0.724402 |
| voluntarios sanos | 0.550874 |
| siguientes afecciones | 0.583572 |
| posibles daños | 0.559702 |
| vÃa oral | 0.551992 |
| largo plazo | 0.555083 |
| carcinoma lobulillar situ | 0.643038 |
| National Cancer Institute | 0.566999 |
| vitamina a | 0.552574 |
| siguientes riesgos | 0.550628 |
| Instituto Nacional | 0.618668 |
| protección ayuda | 0.699167 |
|
| Physician Data Query | 0.746401 |
| Estados Unidos | 0.579171 |
| suficiente ejercicio | 0.906195 |
| siguientes caracterÃsticas | 0.59401 |
| prevención revisa | 0.554009 |
| PDQ Prevención | 0.599371 |
| Menor exposición | 0.569365 |
| siguientes formas | 0.705774 |
| pequeñas llamadas lobulillos | 0.645602 |
| Mayor edad | 0.567138 |
| genes brca1 | 0.883252 |
| conductos.ampliar anatomÃa | 0.589939 |
| siguientes sumarios | 0.661886 |
|
CLICK HERE |
| 2038 |
National Cancer Institute |
Html |
es |
Prevención del cáncer de piel (PDQ®)–Versión para pacientes |
Sumario de información revisada por expertos sobre factores que pueden influir en el riesgo de presentar cáncer de piel y sobre las investigaciones dirigidas a prevenir esta enfermedad. |
| nevo atÃpico | 0.426748 |
| almacena agua | 0.428194 |
| voluntarios sanos | 0.420911 |
| filtros solares | 0.422801 |
| ropa protectora | 0.423732 |
| menor exposición | 0.423337 |
| protector solar | 0.980296 |
| protector solar ayuda | 0.457908 |
| siguientes ejemplos | 0.47268 |
| luz solar | 0.660447 |
| vitamina d | 0.429105 |
| National Cancer Institute | 0.427791 |
| piel melanoma | 0.815892 |
| Instituto Nacional | 0.448341 |
|
| lunares benignos | 0.424057 |
| antecedentes familiares | 0.421492 |
| lámparas solares | 0.426025 |
| suficientes estudios | 0.422469 |
| Physician Data Query | 0.500422 |
| radiación uv | 0.839863 |
| Estados Unidos | 0.55931 |
| vitamina b3 | 0.46569 |
| suficiente ejercicio | 0.427407 |
| prevención revisa | 0.424823 |
| PDQ Prevención | 0.445149 |
| siguientes sustancias | 0.424243 |
| radiación ultravioleta | 0.557367 |
| siguientes sumarios | 0.449523 |
|
CLICK HERE |
| 3424 |
National Cancer Institute |
Html |
es |
Informes de patología |
Hoja informativa que describe el tipo de información que puede aparecer en un informe de patología, el cual contiene los resultados de la examinación visual y microscópica del tejido extirpado durante una biopsia o cirugía. |
| página del nci | 0.749066 |
| cromosoma filadelfia | 0.760969 |
| ¿Cuánto tiempo | 0.803391 |
| leucemia mielógena | 0.766464 |
| tipo southern | 0.748591 |
|
| Detecta fragmentos | 0.751768 |
| simple vista | 0.960274 |
| Instituto Nacional | 0.833257 |
| cuello uterino | 0.83163 |
|
CLICK HERE |
| 4393 |
National Cancer Institute |
Html |
en |
Care for Childhood Cancer Survivors |
Survivorship care for children who have been treated for cancer is important. Get your child's treatment summary, survivorship plan, and recommendations on follow-up care clinics. Learn about long-term and late effects. |
| cancer treatment | 0.326817 |
| child needs | 0.304086 |
| follow-up care plan | 0.413114 |
| Planning fact sheet | 0.303028 |
| type | 0.300894 |
| health care team | 0.507646 |
| children | 0.315621 |
| follow-up care clinics | 0.3448 |
| survivorship clinics | 0.2728 |
| increased risk | 0.28401 |
| clinical trial | 0.299772 |
| survivorship care | 0.448293 |
| follow-up care visits | 0.396149 |
| child’s recovery | 0.291653 |
| Cancer Survivorship Care | 0.352592 |
| physical late effects | 0.431203 |
| survivorship care plan | 0.433534 |
| late side effects | 0.29008 |
| family health history | 0.303512 |
| health problems | 0.288413 |
| cognitive late effects | 0.426207 |
| Treatment dates | 0.285186 |
| radiation therapy | 0.304846 |
| Supportive care | 0.276073 |
| new routines | 0.26175 |
|
| long-awaited time | 0.26767 |
| late effects | 0.939895 |
| child | 0.816649 |
| treatment summary | 0.334731 |
| treatment information | 0.286208 |
| Emotional late effects | 0.333335 |
| survivor support groups | 0.293019 |
| treatment | 0.559585 |
| new phase | 0.261152 |
| post-traumatic stress disorder | 0.292738 |
| follow-up care plans | 0.34673 |
| children’s cancer | 0.274057 |
| palliative care | 0.276488 |
| Childhood Cancer | 0.261784 |
| Late Effects Directory | 0.342069 |
| child receive | 0.286057 |
| mental health support | 0.300564 |
| Survivorship care plans | 0.341053 |
| Family-based care | 0.275482 |
| child’s ability | 0.286297 |
| long-term side effects | 0.358965 |
| cancer | 0.37733 |
| follow-up care | 0.618265 |
| time | 0.296976 |
|
CLICK HERE |
| 16822 |
National Cancer Institute |
Html |
es |
Essiac y Flor Essence (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos sobre el uso de Essiac o Flor Essence como tratamiento para personas con cáncer. Nota: La información contenida en este sumario ya no se actualiza y se ofrece solo con fines de consulta. |
| Centro Nacional | 0.301601 |
| New Hampshire Avenue | 0.301144 |
| Drug Administration | 0.30071 |
| Flor Essence | 0.987323 |
| NCI Best Case | 0.302063 |
| modelos animales | 0.300855 |
| Indiana University-Purdue University | 0.301652 |
| datos bibliográficos pubmed | 0.301216 |
| siguientes preguntas | 0.300694 |
| productos essiac | 0.309556 |
| modelo animal | 0.300781 |
| PDQ Essiac | 0.318217 |
| National Cancer Institute | 0.301364 |
| Royal Cancer Commission | 0.301752 |
| Olmo resbaladizo | 0.301149 |
| siguientes riesgos | 0.300858 |
| Instituto Nacional | 0.309533 |
| Salud Complementaria | 0.302607 |
|
| Visuals Online | 0.300813 |
| complementarias revisa | 0.30115 |
| Physician Data Query | 0.304689 |
| Sloan Kettering Cancer | 0.301678 |
| Estados Unidos | 0.332086 |
| siguientes estudios | 0.301314 |
| libre uso | 0.301062 |
| distintos resultados | 0.300776 |
| únicos efectos | 0.301309 |
| ratón p388 | 0.301025 |
| página manejo | 0.300756 |
| ¿El tratamiento | 0.301379 |
| Nueva York | 0.300871 |
| ¿Los beneficios | 0.30071 |
| juntos cam | 0.300681 |
| Series Program | 0.300695 |
| medicina complementaria | 0.332457 |
|
CLICK HERE |